Digital health implementation in clinical trials has evolved beyond technical deployment to focus on actual operational value realization. While platforms meeting FDA guidance on remote data acquisition, decentralized trial elements, and electronic systems—alongside ICH E6(R3) standards—represent necessary technical achievement, they frequently fail to deliver meaningful outcomes if poorly integrated into workflows or inconsistently adopted. Dr. Harsh Shah proposes a five-layer framework addressing this "last mile" implementation challenge: Technical Fitness, Workflow Fit, Adoption, Data Reliability, and Outcome Conversion. Traditional success metrics measuring configuration completion, validation passage, and site activation mask deeper failures, such as electronic clinical outcome assessment platforms deployed to all sites yet generating high participant support needs and parallel paper workarounds, or analytics platforms producing unactionable alerts. Shah's diagnostic model—Realized Value equals the multiplication of all five layers—demonstrates that weakness in any single component compromises overall value delivery. This framework shifts evaluation emphasis from binary go-live milestones toward sustained measurement of whether technology genuinely improves trial execution and decision-making, establishing necessary standards for mature digital implementation in drug development.

Researchers from Chinese universities conducted a scoping review examining how digital phenotyping technologies can monitor and predict mental health outcomes in people with diabetes. The review searched six English and four Chinese databases through September 2026, ultimately analyzing ten studies. The evidence reveals that digital phenotyping enables real-time mental health monitoring through continuous glucose monitoring devices, passive smartphone sensing, voice analysis, and ecological momentary assessment. Machine learning algorithms were commonly employed for risk prediction modeling; however, most studies operated at the group level rather than individual level, with limited use of n-of-1 analysis or subgroup prediction for personalized outcomes. The review identified significant gaps, including insufficient external validation of models and an absence of intervention studies. Given that depression, anxiety, and diabetes-related distress frequently co-occur and directly impact glycemic control and complication risk, this technology offers promising potential for more objective, real-time mental health assessment compared to traditional subjective scales. Future development should prioritize individualized risk prediction models, robust validation protocols, and intervention trials to fully realize digital phenotyping's clinical utility in diabetes care.

Digital health app engagement remains a critical challenge, with industry benchmarks revealing that approximately fifty percent of users remain active after thirty days, declining to just one in five after a year. This engagement problem extends beyond mere app retention metrics, significantly impacting patient outcomes and clinical effectiveness. When patients perceive that tracking effort outweighs perceived benefits—particularly with repetitive reminders, manual data entry, and limited feedback—disengagement follows, leading to missed treatment actions, reduced clinician visibility between appointments, and lost patient-generated data valuable for real-world evidence. Successful patient companion app development requires embedding engagement strategies from inception rather than treating them as afterthoughts. Effective approaches must account for evolving patient motivations, integration with daily routines, caregiver involvement, alignment with clinical workflows, and clear evidence requirements. This comprehensive design perspective transforms patient engagement from a retention metric into a fundamental design challenge, ensuring digital health products deliver sustained value throughout patients' treatment journeys.

The Centers for Medicare & Medicaid Services has launched the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a voluntary 10-year initiative beginning July 5, 2026, designed to expand technology-supported chronic care delivery for Medicare beneficiaries. The program addresses chronic conditions affecting over two-thirds of Medicare enrollees, including hypertension, diabetes, chronic musculoskeletal pain, and depression. ACCESS introduces Outcome-Aligned Payments (OAPs), a novel reimbursement approach that provides participating organizations recurring payments for managing qualifying conditions, with full compensation contingent upon achieving measurable health outcomes. This addresses a critical gap in Original Medicare's fee-for-service model, which historically cannot adequately support technology-enabled care delivery. New disease tracks for heart failure, COPD, substance use disorder, tobacco cessation, and chronic musculoskeletal pain launch April 1, 2027. Leading medical societies and major health plans have pledged support for ACCESS-aligned payment options. The model particularly benefits patients in underserved communities with limited local care access, including rural areas, by enabling continuous digital health support beyond traditional office visits.

The article examines the urgent need for a sovereign approach to artificial intelligence in healthcare, beginning with a diagnosis of systemic failures in centralized digital platforms. Drawing on Cory Doctorow's concept of "platform enshitification," the piece describes how digital health ecosystems have become extractive silos that undermine patient agency and erode trust through data breaches and behavioral manipulation. In response, the "Building Together" platform has been developed as a sovereign mental health ecosystem designed to address these vulnerabilities. The article emphasizes that rapid AI advancement—exemplified by Anthropic's Claude Mythos 5 deployment through Project Glasswing—is outpacing regulatory strategies and fundamentally threatening traditional cybersecurity for healthcare data. The Mythos model's capacity for autonomous vulnerability discovery and network reconnaissance has rendered centralized firewall protections obsolete. Consequently, healthcare systems must transition toward decentralized, cryptographically verifiable trust frameworks managed at the data source. Canadian technology leaders Don and Alex Tapscott have advocated for establishing a national digital identity framework to help the nation adapt to this technological shift, highlighting the critical importance of building resilient healthcare infrastructure.

Attention-deficit/hyperactivity disorder affects millions of school-aged children globally, presenting with inattention, executive dysfunction, and motor impulsivity that often lead to academic underachievement and social difficulties. While pharmacotherapy remains a primary treatment approach, concerns about adverse effects like appetite suppression and growth inhibition, combined with limited access to specialized behavioral therapies, have prompted exploration of alternative interventions. A comprehensive meta-analysis synthesizing thirty-seven randomized controlled trials examined digital therapeutics as scalable treatment options for pediatric ADHD. The analyzed interventions included four technological categories: computer-based cognitive programs, serious video games, exergames, and virtual reality environments. Unlike passive screen use, these structured digital tools leverage neuroplasticity through adaptive cognitive stimulation and closed-loop feedback mechanisms, potentially modulating dopaminergic pathways to improve attention spans without pharmacologic toxicity. The pooled evidence demonstrates statistically significant improvements in both core ADHD symptoms and broader neuropsychological performance metrics. These findings are particularly significant as digital therapeutics offer objective behavioral tracking, scalability across diverse settings, and accessible alternatives to traditional treatment modalities, representing a valuable complement to existing clinical approaches in pediatric ADHD management.

Data privacy represents a critical yet underrecognized public health crisis with profound mental health implications. According to Dr. Patrick Fisher, a licensed clinician and founder of TheraPetic® Healthcare Provider Group, millions of individuals make consequential mental health decisions—including whether to pursue therapy or fill prescriptions—based on justified fears about their digital data exposure. Fisher's doctoral research on support animal therapeutic outcomes revealed that invisible stressors produce measurable suffering, directly informing his development of MyDataKey™ and his contribution to Volume 6 of The Invisible Series titled "The Invisible Data." The core argument extends beyond conventional data security concerns like identity theft to encompass intimate psychological vulnerability. Health records, search histories, therapy app usage, and prescription data collectively create detailed psychological profiles; unauthorized exposure violates psychological safety and control. In clinical terms, loss of control ranks among the strongest predictors of anxiety and depression. The contemporary digital environment systematically engineered chronic low-grade loss of control affecting billions through data-harvesting applications, telehealth platforms, and behavioral tracking by advertisers. Fisher identifies this pervasive condition as "surveillance anxiety"—chronic psychological distress resulting from awareness of monitoring without meaningful consent. This perspective fundamentally reframes data privacy from a technical issue to an essential mental health imperative requiring urgent clinical and ethical attention.

Digital healthcare has transformed patient engagement through apps offering tracking, coaching, diagnostics, and therapy. At the core is Software as a Medical Device (SaMD), which differs fundamentally from consumer digital health tools based on intended purpose. SaMD targets medical outcomes such as diagnosis, treatment, or disease monitoring, while consumer apps focus on wellness and lifestyle. This distinction determines regulatory requirements, evidence standards, engineering controls, and commercialization strategies. The global medtech market has surpassed $680 billion in 2025 and is projected to reach $1.3 trillion by 2029, with SaMD representing one of the fastest-growing segments. Real-world examples include LumineticsCore for diabetic retinopathy detection, reSET for substance use disorder treatment, EndeavorRx for ADHD attention improvement, and BlueStar for diabetes management—all FDA-authorized products. Understanding whether software serves medical or wellness purposes is critical, as products often evolve into regulatory gray zones. This classification fundamentally shapes product development, validation approaches, and market strategy, making clarity essential for successful deployment.

Negative symptoms in schizophrenia-spectrum disorders, particularly avolition and asociality, remain highly disabling and treatment-resistant. While clinician-rated scales like the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale have improved assessment, they rely on infrequent interviews and retrospective reporting, missing real-world behavioral dynamics. This narrative review examines whether artificial intelligence can transform passive digital phenotyping—continuous data collection via smartphones and wearable sensors capturing mobility, physical activity, sleep, social rhythms, and speech acoustics—into clinically valid endpoints for negative symptoms. The authors propose a construct-to-endpoint pipeline integrating construct definition, multimodal representation learning, and clinical validation to create interpretable digital markers enabling just-in-time adaptive interventions. Current evidence demonstrates consistent but modest associations between passive sensing modalities and negative symptoms; however, single-modality correlations alone cannot establish valid endpoints. A qualified digital endpoint requires demonstrating analytical validity, clinical validity, longitudinal sensitivity, external transportability, and patient meaningfulness. Significant challenges remain across data-level issues such as resolution mismatch and device heterogeneity, inferential risks including environmental confounding and algorithmic bias, and ethical-regulatory concerns, underscoring the complexity of translating sensor data into clinically actionable insights.

PROCLE represents an innovative advancement in remote therapeutic monitoring through an AI-powered, mobile-first platform designed to personalize patient care delivery. The system utilizes artificial intelligence algorithms to identify optimal care programs tailored to individual patient needs, enabling healthcare providers to coordinate comprehensive treatment through a single unified interface. This approach eliminates fragmentation by consolidating multiple care pathways and multidisciplinary teams into one cohesive platform. A distinctive feature of PROCLE is its flexibility to support both traditional Fee-for-Service and Value-Based Care models, making it adaptable across diverse healthcare economic structures. The mobile-first architecture ensures accessibility and engagement by allowing patients to access monitoring and care coordination through smartphone and portable devices. By automating the matching process between patients and appropriate care programs, PROCLE reduces clinical decision-making burden while potentially improving outcomes through evidence-based program selection. The platform's ability to orchestrate coordinated care across multiple providers addresses a critical gap in fragmented healthcare systems. This solution holds particular significance for organizations transitioning to value-based models and those seeking to enhance remote patient engagement and monitoring capabilities in increasingly digital healthcare environments.

Artificial intelligence is transforming the management of neuropsychiatric disorders by moving beyond diagnostic assistance toward adaptive intervention and personalized disease management. This comprehensive review examines AI-driven approaches for neuropsychiatric assessment and treatment, encompassing computer vision-based behavioral analysis, wearable sensing technologies, neuroimaging biomarkers, digital therapeutics, virtual reality, social robotics, and brain-computer interfaces. A key innovation discussed is the emergence of closed-loop frameworks that combine real-time patient state estimation with adaptive intervention strategies, enabling continuous therapeutic optimization rather than passive observation. However, significant challenges persist, including integration of phenotyping with intervention systems, limited translation from experimental settings to clinical practice, multimodal data representation, interpretability, and generalizability across diverse populations and devices. The research, authored by scientists from Wuhan University, Guangzhou Women and Children's Medical Center, and other Chinese institutions, identifies that prediction accuracy is no longer the primary bottleneck in AI-driven neuropsychiatry. Instead, the critical challenge lies in connecting continuous patient-state estimation with clinically actionable adaptive responses. The review concludes by proposing future directions toward developing clinically grounded, human-AI collaborative neuropsychiatric systems that can effectively address the substantial global disease burden caused by conditions including Alzheimer's disease and Parkinson's disease.

Digital phenotyping leverages smartphone passive sensing to detect depression relapse before clinical symptoms emerge by analyzing behavioral patterns like typing rhythm, movement, and sleep cycles. Rather than relying on population averages, this approach establishes individual baselines to identify meaningful deviations signaling potential relapse. The field has matured from consumer wellness applications toward hospital-affiliated and specialty clinic deployments using vetted platforms under explicit protocols. However, significant implementation barriers remain: designing consent models patients genuinely understand, reducing alert fatigue for clinicians, and establishing clear FDA regulatory pathways for software as a medical device that distinguish clinical tools from wellness trackers. Early research demonstrated linkages between inactive smartphone features and mood state, though high-profile startup failures highlighted privacy and business model vulnerabilities. Recent progress emphasizes reproducibility across diverse populations, as phenotyping models developed in one cohort frequently fail when applied elsewhere due to variations in keyboard layouts, commute patterns, and cultural phone-use norms. Published research in journals like npj Digital Medicine increasingly standardizes features, preprocessing methods, and outcome definitions. By 2026, digital phenotyping for depression represents a narrower but more clinically grounded proposition with genuine potential for preventive psychiatry at scale, contingent on resolving regulatory and workflow integration challenges.

Remote Therapeutic Monitoring (RTM) represents a frequently underutilized yet highly valuable component of CMS care-management programs. Introduced in 2022, RTM monitors non-physiologic therapeutic data across three anchor domains: musculoskeletal status, respiratory status, and cognitive behavioral therapy, enabling physical therapists, occupational therapists, and speech-language pathologists to serve as billing practitioners. Unlike Remote Patient Monitoring, RTM operates with national non-facility averages and allows concurrent billing alongside other programs for the same patient with different practitioners. Sansera's CCM360 platform collects patient-reported outcomes including pain scores, exercise completion, and validated instruments through conversational SMS and app-based flows, with natural language processing identifying clinical signals from free-text responses. The platform enforces strict billing separation, ensuring compliance with the 16-day rule and maintaining independent time ledgers for each program. Automated administration of validated instruments, trending, and integration into therapist documentation provide both clinical value and audit evidence. Organizations offering rehabilitation, respiratory care, or behavioral health services can capture significant unrealized revenue while generating meaningful clinical data through RTM implementation.

CPT code 99457 is the billing code for remote physiologic monitoring treatment management services covering the first 20 minutes of clinical care per calendar month. This code requires involvement from a physician, qualified healthcare professional, or clinical staff under general supervision, and mandates at least one real-time interactive communication with the patient or caregiver. The code is part of the remote patient monitoring family alongside 99453, 99454, 99458, and from January 1, 2026, codes 99445 and 99470. Device setup and supply are billed separately under distinct codes, while additional 20-minute increments use add-on code 99458. Practices cannot report 99091 during the same period as 99457. New regulations expanding the RPM family include 99470 for months with 10-19 minutes of management time and 99445 for device supply covering 2-15 days of data. Accurate coding is critical for clean claims and timely reimbursement, making automation tools valuable for reducing denials and ensuring compliance with evolving CMS guidelines.

Remote Patient Monitoring (RPM) enables patients to collect their own health data using connected medical devices that automatically transmit information to healthcare providers for treatment and condition management. While RPM services—including Digital Mental Health Treatment, Remote Physiologic Monitoring (RPM), and Remote Therapeutic Monitoring (RTM)—are not classified as telehealth under Medicare definitions, the Centers for Medicare and Medicaid Services (CMS) established separate reimbursement pathways beginning in 2018. Remote physiologic monitoring codes (99091, 99453, 99454, 99457, 99458) cover the collection and interpretation of physiologic data, while remote therapeutic monitoring codes (98975, 98976, 98977, 98980, 98981) serve psychiatrists, nurse practitioners, and physical therapists, allowing non-physiological data collection. Each code carries specific requirements outlined in code descriptions. Additionally, chronic care management, principal care management, and transitional care management services may incorporate remote monitoring applications. CMS has progressively expanded coverage across multiple calendar years, with detailed billing processes and policies documented in the CY 2021, 2022, 2024, and 2026 Physician Fee Schedule Final Rules, reflecting the growing integration of remote monitoring into standard clinical practice.

Researchers investigated smartphone passive digital phenotyping as a novel diagnostic and monitoring tool for frontotemporal lobar degeneration (FTLD), a progressive neurodegenerative disease affecting behavior, language, and motor function. Passive digital phenotyping leverages smartphone sensors and usage patterns to continuously collect behavioral and cognitive data without requiring active patient participation, offering a non-invasive alternative to traditional clinical assessments. The study evaluated how metrics derived from smartphone interaction—including typing patterns, app usage frequency, screen time, and movement data from accelerometers—could detect and track FTLD-related cognitive and functional decline. Key findings demonstrated that smartphone-derived markers showed meaningful correlations with disease severity and progression, potentially enabling early detection and real-time monitoring of symptom changes. This approach matters significantly because FTLD typically progresses rapidly and currently lacks disease-modifying treatments, making early diagnosis and continuous monitoring critical for patient management and clinical trial enrollment. By transforming smartphones into continuous biosensors, passive digital phenotyping could improve clinical trial recruitment, reduce assessment burden on patients, and provide clinicians with objective data for treatment decisions and disease tracking in FTLD populations.

Mental health wearables represent a transformative approach to managing psychological well-being through innovative technology. These devices, including wristbands and EEG headsets, utilize advanced sensors to monitor physiological metrics such as heart rate, electrodermal activity, and brainwave patterns. By collecting and analyzing data on stress levels, sleep patterns, and emotional states, these wearables provide real-time feedback and actionable insights that were previously unavailable outside clinical settings. Key features include stress alerts with suggested interventions like breathing exercises, sleep cycle tracking with personalized improvement recommendations, and continuous monitoring capabilities that enable early detection of potential mental health issues. The primary advantage lies in objective, continuous data collection rather than relying on periodic therapeutic visits or self-reported information. This approach empowers users to proactively manage their mental health while providing healthcare professionals with comprehensive insights. As mental health challenges become increasingly prevalent, these accessible, high-tech solutions offer significant potential to democratize mental health care and improve outcomes across diverse populations seeking anxiety management, sleep improvement, and enhanced emotional well-being.

Digital therapeutics represent a distinct category from wellness apps when they make clinical claims about treating, managing, or preventing specific conditions. The critical distinction lies in evaluating products through three interconnected lenses: regulatory clearance, clinical evidence, and reimbursement pathways. Products claiming medical benefits must demonstrate validation against defined endpoints comparable to standard-of-care treatments and secure appropriate regulatory authorization. However, robust trial data alone proves insufficient for commercial success without durable reimbursement mechanisms and established clinician workflows. Engagement metrics such as daily active users or session length indicate usage patterns rather than clinical outcomes; evaluators should assess what proportion of engaged users actually achieved studied endpoints. Real-world evidence collected post-launch differs meaningfully from pivotal trial data and serves different purposes. Products integrating seamlessly into existing clinical workflows, providing treating clinicians with adherence data and escalation alerts, demonstrate superior sustainability compared to purely consumer-facing tools. The digital therapeutics market ultimately succeeds through alignment of clinical claims with regulatory pathways and reimbursement routes, moving beyond app store listings toward integrated healthcare delivery systems.

Remote Therapeutic Monitoring (RTM) represents a significant advancement in digital healthcare delivery, now expanded with two new CPT codes (98985 and 98979) for musculoskeletal care in the 2026 Medicare Physician Fee Schedule, effective January 1, 2026. RTM uses digital technology to track patient health status, treatment progress, and adherence to care plans between clinical visits. This innovation addresses a critical healthcare challenge: musculoskeletal conditions cost the healthcare system approximately $600 billion annually—more than double heart disease costs. While early and adherent physical therapy can substantially reduce these expenses and improve outcomes, only 30 percent of patients successfully complete prescribed home exercise programs, and up to 80 percent forget critical information provided during clinic visits. RTM bridges this gap by enabling therapists to remotely support patient progress, promote adherence to home exercise programs, and track outcomes using digital tools. Originally approved by the Centers for Medicare and Medicaid Services in 2022, RTM's expanded code set represents the healthcare industry's continued integration of digital technology, following the evolution of Electronic Medical Records and patient wellness trackers, creating enhanced connectivity between providers and patients.

Patient preferences in recovery applications reveal critical insights for behavioral health organizations seeking to improve digital tool adoption and engagement. Research shows that while 45% of patients have used recovery apps or websites to support their treatment, long-term retention remains challenging. A significant trust gap undermines sustained use: 44% of mental health apps share user data with third parties, nearly 41% lack privacy policies, and Mozilla reviews found that 60% of apps failed minimum privacy and security standards, with only PTSD Coach and Wysa meeting rigorous criteria across 27 applications tested. Patients consistently prefer apps that are simple, private, and integrated with clinical care rather than standalone tools. Engagement strategies vary in effectiveness—push notifications increased app opens within one hour by 3.5 times, but fixed daily alerts did not improve long-term adoption. For individuals in substance use disorder recovery, privacy protection carries particular weight, affecting employment, custody, and legal exposure. Recovery app fit influences staff workflows, documentation, risk response, and no-show rates. By designing tools that reduce friction, grant users control, protect data transparently, and connect seamlessly to treatment, behavioral health organizations can meaningfully improve patient outcomes and engagement.